NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ozanimod

Last Revision: September 21, 2020.

Estimated reading time: 1 minute

CASRN: 1306760-87-1

image 341101951 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

Although ozanimod and its active metabolites are highly bound in maternal plasma and unlikely to reach the breastmilk in large amounts, it is potentially toxic to the breastfed infant. Because there is no published experience with ozanimod during breastfeeding, expert opinion generally recommends that the closely related drug fingolimod should be avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1-5] However, the manufacturer's labeling does not recommend against the use of ozanimod in breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta

References

1.
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol. 2014;124:1157–68. [PubMed: 25415167]
2.
Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835–43. [PubMed: 23319073]
3.
Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: Therapeutic considerations. J Neurol. 2013;260:1202–14. [PubMed: 22926165]
4.
Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
5.
Kaplan TB. Management of demyelinating disorders in pregnancy. Neurol Clin. 2019;37:17–30. [PubMed: 30470273]

Substance Identification

Substance Name

Ozanimod

CAS Registry Number

1306760-87-1

Drug Class

Breast Feeding

Lactation

Immunosuppressive Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Fingolimod[Drugs and Lactation Database (...]
    Review Fingolimod
    . Drugs and Lactation Database (LactMed). 2006
  • Review Siponimod[Drugs and Lactation Database (...]
    Review Siponimod
    . Drugs and Lactation Database (LactMed). 2006
  • Review Dasatinib[Drugs and Lactation Database (...]
    Review Dasatinib
    . Drugs and Lactation Database (LactMed). 2006
  • Review Linagliptin[Drugs and Lactation Database (...]
    Review Linagliptin
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ledipasvir[Drugs and Lactation Database (...]
    Review Ledipasvir
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...